Newswise — July 8, 2021 – Women with recurrent urinary tract infections (UTIs) experience frustration related to their treatment – particularly the risks from repeated use of antibiotics, according to a focus group study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
“This study was prompted by our experience treating countless women with recurrent UTIs referred to our specialized Female Pelvic Medicine and Reconstructive Surgery center,” comments senior author Ja-Hong Kim, MD, of UCLA Center of Women’s Pelvic Health. “The vast majority were understandably dissatisfied with their care pathway, which was primarily antibiotic-focused with minimal effort spent on patient education and prevention strategies.”
Lead author Victoria C.S. Scott, MD, of Cedars-Sinai Medical Center, Beverly Hills, Calif adds, “It’s important for patients with this chronic condition to feel empowered in sharing their concerns with physicians regarding their health, quality of life and medical treatment and for physicians to respond to these concerns.”
New strategies needed ‘to minimize and target antibiotic use’
More than half of women will develop a UTI sometime during their lives, and about one-fourth experience recurrent UTIs. Episodes of UTI have a major impact on patients’ lives – including pain and other symptoms, reduced quality of life, and repeated courses of antibiotics for prevention and treatment.
“In our experience, many patients labelled with recurrent UTI are either misdiagnosed or mistreated without following the guidelines set forth by specialty societies,” says Dr. Kim. “It became clear that a paradigm shift in recurrent UTI management was needed, starting with patient-centered research to assess gaps in the current UTI treatment algorithm.” The researchers performed a series of focus groups, with a total of 29 patients participating.
Analysis of the discussions identified several themes related to negative effects associated with antibiotic use. The women were well aware of the risks of developing antibiotic resistance and collateral damage from overuse or inappropriate use of antibiotics. Some patients developed infection with antibiotic-resistant C. difficile bacteria, in one case leading to hospitalization.
The patients also voiced concern about taking antibiotics when they didn’t have an infection. Many believed they had been given antibiotics for other causes of urinary symptoms – particularly overactive bladder, which commonly occurs in women with recurrent UTIs but causes less-severe symptoms.
Other themes centered on resentment of the medical profession. The women expressed irritation with physicians for “throwing antibiotics” at them without presenting other, non-antibiotic options for treating recurrent UTIs. They also felt the medical profession underestimated the impact of recurrent UTIs on their lives. The women felt an urgent need for more research on non-antibiotic options, with a special interest in “natural” or “alternative” treatments for prevention of recurrent UTIs.
However, some women shared they were satisfied with their care – particularly those treated by a physician specializing in Female Pelvic Medicine and Reconstructive Surgery. Patients were more likely to be satisfied if they felt their doctor understood their problems and had a system for rapid diagnosis and treatment when UTI episodes occurred.
“Physicians must investigate patients’ recurrent UTI experiences and their perceptions of antibiotics during counseling to address their concern over antibiotic overuse,” says Dr. Scott. The researchers follow and recommend a strategy of delaying antibiotics until urine culture results are available – as endorsed by the American Urological Association (AUA) and other specialty societies.
Dr. Kim concludes: “There are exciting research developments underway, including the utilization of point-of-care rapid diagnostic assays to accurately and selectively treat UTIs as well as studies to understand the impact of vaginal microbiome on voiding dysfunction. We hope these efforts will pave the way to improved patient experience.”
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.